milnacipran ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1808 92623-85-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • milnacipran
  • midalcipran
  • (+/-)-Milnacipran
  • milnacipran hydrochloride
  • milnacipran HCl
A cyclopropanecarboxamide serotonin and norepinephrine reuptake inhibitor (SNRI) that is used in the treatment of FIBROMYALGIA.
  • Molecular weight: 246.35
  • Formula: C15H22N2O
  • CLOGP: 1.91
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 1
  • TPSA: 46.33
  • ALOGS: -2.30
  • ROTB: 5

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.10 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 55 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 11.60 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 84 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 4.51 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 8.17 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.87 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 6.48 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Jan. 14, 2009 FDA CYPRESS BIOSCIENCE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Suicidal ideation 136.71 17.75 86 7075 62335 63419526
Drug hypersensitivity 98.26 17.75 146 7015 310541 63171320
Serotonin syndrome 93.04 17.75 51 7110 28631 63453230
Somatic delusion 77.26 17.75 17 7144 575 63481286
Hyperhidrosis 72.05 17.75 74 7087 107762 63374099
Nausea 65.94 17.75 228 6933 854243 62627618
Migraine 60.29 17.75 66 7095 103280 63378581
Hot flush 55.38 17.75 46 7115 51113 63430748
Blepharospasm 55.32 17.75 22 7139 5974 63475887
Headache 50.42 17.75 171 6990 633070 62848791
Urine odour abnormal 43.91 17.75 19 7142 6370 63475491
Heart rate increased 42.91 17.75 53 7108 94185 63387676
Persistent genital arousal disorder 41.72 17.75 9 7152 277 63481584
Gastrointestinal motility disorder 41.10 17.75 17 7144 5102 63476759
Abnormal faeces 39.98 17.75 17 7144 5463 63476398
Depression 38.79 17.75 75 7086 196417 63285444
Blood thyroid stimulating hormone normal 36.58 17.75 7 7154 116 63481745
Insomnia 36.35 17.75 77 7084 215175 63266686
Taste disorder 35.42 17.75 21 7140 13641 63468220
Anger 34.54 17.75 20 7141 12436 63469425
Oral discomfort 34.42 17.75 18 7143 9183 63472678
Memory impairment 32.79 17.75 49 7112 104209 63377652
Chromaturia 31.53 17.75 21 7140 16696 63465165
Blood pressure increased 30.92 17.75 61 7100 162001 63319860
Tremor 27.95 17.75 52 7109 132187 63349674
Musculoskeletal discomfort 27.84 17.75 20 7141 17947 63463914
Lip swelling 27.66 17.75 25 7136 31038 63450823
Crying 27.36 17.75 22 7139 23321 63458540
Aphasia 26.37 17.75 25 7136 32975 63448886
Flushing 26.08 17.75 37 7124 75050 63406811
Homicidal ideation 25.57 17.75 9 7152 1743 63480118
Palpitations 24.65 17.75 45 7116 112725 63369136
Epilepsy 24.53 17.75 22 7139 27043 63454818
Vomiting 24.50 17.75 126 7035 559491 62922370
Paraesthesia 21.81 17.75 52 7109 156914 63324947
Irritability 21.58 17.75 22 7139 31672 63450189
Disturbance in attention 21.56 17.75 24 7137 38165 63443696
Drug withdrawal syndrome 20.59 17.75 20 7141 27174 63454687
Withdrawal syndrome 19.61 17.75 17 7144 19980 63461881
Feeling abnormal 19.38 17.75 48 7113 148344 63333517
Hypoaesthesia 18.44 17.75 51 7110 168342 63313519
Ear infection 18.19 17.75 22 7139 38191 63443670
Swollen tongue 18.17 17.75 21 7140 34779 63447082
Blood catecholamines increased 18.04 17.75 3 7158 21 63481840
Panic attack 17.99 17.75 17 7144 22314 63459547

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Urinary retention 48.56 26.18 23 1022 36265 34919621
Suicidal ideation 46.22 26.18 23 1022 40365 34915521
Agoraphobia 40.87 26.18 7 1038 245 34955641
Bicytopenia 34.66 26.18 9 1036 2375 34953511
Dysuria 32.62 26.18 16 1029 27136 34928750
Neurosis 29.69 26.18 5 1040 158 34955728
Urinary hesitation 28.59 26.18 8 1037 2794 34953092

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Suicidal ideation 129.32 18.90 78 6118 76262 79661930
Drug hypersensitivity 109.45 18.90 125 6071 298791 79439401
Somatic delusion 80.31 18.90 17 6179 701 79737491
Serotonin syndrome 68.51 18.90 43 6153 44984 79693208
Migraine 64.89 18.90 54 6142 87439 79650753
Blepharospasm 63.84 18.90 22 6174 5829 79732363
Headache 52.36 18.90 139 6057 653633 79084559
Gastrointestinal motility disorder 47.90 18.90 18 6178 6104 79732088
Persistent genital arousal disorder 45.22 18.90 9 6187 272 79737920
Urine odour abnormal 43.89 18.90 17 6179 6256 79731936
Hyperhidrosis 43.28 18.90 56 6140 151436 79586756
Nausea 41.53 18.90 165 6031 957031 78781161
Heart rate increased 41.52 18.90 49 6147 120675 79617517
Hot flush 40.93 18.90 34 6162 54843 79683349
Abnormal faeces 40.80 18.90 17 6179 7554 79730638
Oral discomfort 39.79 18.90 18 6178 9742 79728450
Blood thyroid stimulating hormone normal 39.08 18.90 7 6189 118 79738074
Memory impairment 37.83 18.90 45 6151 111689 79626503
Taste disorder 37.04 18.90 20 6176 15803 79722389
Urinary hesitation 31.41 18.90 12 6184 4254 79733938
Anger 30.20 18.90 18 6178 17144 79721048
Lip swelling 29.78 18.90 25 6171 40886 79697306
Depression 29.46 18.90 57 6139 216733 79521459
Hypoaesthesia 29.21 18.90 51 6145 179301 79558891
Chromaturia 28.07 18.90 20 6176 25726 79712466
Musculoskeletal discomfort 27.80 18.90 18 6178 19817 79718375
Crying 27.69 18.90 19 6177 23024 79715168
Aphasia 26.90 18.90 25 6171 46707 79691485
Flushing 25.76 18.90 33 6163 88235 79649957
Withdrawal syndrome 25.08 18.90 19 6177 26835 79711357
Anxiety 24.13 18.90 57 6139 248455 79489737
Insomnia 23.55 18.90 56 6140 245114 79493078
Agoraphobia 23.42 18.90 6 6190 572 79737620
Pain 23.25 18.90 112 6084 703690 79034502
Ear infection 22.93 18.90 20 6176 34412 79703780
Drug withdrawal syndrome 22.79 18.90 20 6176 34698 79703494
Paraesthesia 22.30 18.90 45 6151 176278 79561914
Blood pressure increased 22.18 18.90 50 6146 211310 79526882
Epilepsy 21.88 18.90 21 6175 40839 79697353
Disturbance in attention 21.51 18.90 23 6173 50778 79687414
Bicytopenia 20.27 18.90 9 6187 4661 79733531
Panic attack 20.15 18.90 16 6180 24200 79713992
Palpitations 19.31 18.90 35 6161 126575 79611617

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N06AX17 NERVOUS SYSTEM
PSYCHOANALEPTICS
ANTIDEPRESSANTS
Other antidepressants
FDA MoA N0000000102 Norepinephrine Uptake Inhibitors
FDA MoA N0000000109 Serotonin Uptake Inhibitors
MeSH PA D000700 Analgesics
MeSH PA D018712 Analgesics, Non-Narcotic
MeSH PA D002491 Central Nervous System Agents
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D014179 Neurotransmitter Uptake Inhibitors
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D018689 Sensory System Agents
MeSH PA D000068760 Serotonin and Noradrenaline Reuptake Inhibitors
FDA EPC N0000175749 Serotonin and Norepinephrine Reuptake Inhibitor

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Fibromyalgia indication 203082005 DOID:631
Tachyarrhythmia contraindication 6285003
Urinary tract obstruction contraindication 7163005 DOID:5200
Alcoholism contraindication 7200002
Hypertensive disorder contraindication 38341003 DOID:10763
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Syndrome of inappropriate vasopressin secretion contraindication 55004003 DOID:3401
Acute nephropathy contraindication 58574008
Blood coagulation disorder contraindication 64779008 DOID:1247
Hyponatremia contraindication 89627008
Seizure disorder contraindication 128613002
Liver function tests abnormal contraindication 166603001
Mania contraindication 231494001
Hypomania contraindication 231496004
Disease of liver contraindication 235856003 DOID:409
Suicidal contraindication 267073005
Serotonin syndrome contraindication 371089000
Angle-closure glaucoma contraindication 392291006 DOID:13550




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.64 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
100MG SAVELLA ABBVIE N022256 Jan. 14, 2009 RX TABLET ORAL 6602911 Jan. 14, 2023 MANAGEMENT OF FIBROMYALGIA (FM)
12.5MG SAVELLA ABBVIE N022256 Jan. 14, 2009 RX TABLET ORAL 6602911 Jan. 14, 2023 MANAGEMENT OF FIBROMYALGIA (FM)
25MG SAVELLA ABBVIE N022256 Jan. 14, 2009 RX TABLET ORAL 6602911 Jan. 14, 2023 MANAGEMENT OF FIBROMYALGIA (FM)
50MG SAVELLA ABBVIE N022256 Jan. 14, 2009 RX TABLET ORAL 6602911 Jan. 14, 2023 MANAGEMENT OF FIBROMYALGIA (FM)
100MG SAVELLA ABBVIE N022256 Jan. 14, 2009 RX TABLET ORAL 7994220 Sept. 19, 2029 MANAGEMENT OF FIBROMYALGIA
12.5MG SAVELLA ABBVIE N022256 Jan. 14, 2009 RX TABLET ORAL 7994220 Sept. 19, 2029 MANAGEMENT OF FIBROMYALGIA
25MG SAVELLA ABBVIE N022256 Jan. 14, 2009 RX TABLET ORAL 7994220 Sept. 19, 2029 MANAGEMENT OF FIBROMYALGIA
50MG SAVELLA ABBVIE N022256 Jan. 14, 2009 RX TABLET ORAL 7994220 Sept. 19, 2029 MANAGEMENT OF FIBROMYALGIA

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Sodium-dependent serotonin transporter Transporter INHIBITOR Ki 7.29 WOMBAT-PK CHEMBL
Sodium-dependent noradrenaline transporter Transporter INHIBITOR Ki 7.60 WOMBAT-PK CHEMBL
Sodium-dependent dopamine transporter Transporter IC50 5.21 CHEMBL
Glutamate receptor ionotropic, NMDA 2A Ion channel IC50 5.20 WOMBAT-PK
Sodium-dependent serotonin transporter Transporter IC50 7.33 CHEMBL
Sodium-dependent dopamine transporter Transporter IC50 4.43 CHEMBL
Transporter Transporter IC50 7.52 CHEMBL

External reference:

IDSource
4025253 VUID
N0000179785 NUI
D01107 KEGG_DRUG
101152-94-7 SECONDARY_CAS_RN
4025253 VANDF
4028372 VANDF
C1533126 UMLSCUI
CHEBI:135005 CHEBI
CHEMBL252923 ChEMBL_ID
CHEMBL259209 ChEMBL_ID
DB04896 DRUGBANK_ID
CHEMBL4297064 ChEMBL_ID
D000078764 MESH_DESCRIPTOR_UI
65833 PUBCHEM_CID
7436 IUPHAR_LIGAND_ID
5701 INN_ID
G56VK1HF36 UNII
30003 RXNORM
26139 MMSL
d06635 MMSL
008263 NDDF
008264 NDDF
441641002 SNOMEDCT_US
442542004 SNOMEDCT_US
442642007 SNOMEDCT_US
CHEMBL1237129 ChEMBL_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Savella HUMAN PRESCRIPTION DRUG LABEL 1 0456-1510 TABLET, FILM COATED 100 mg ORAL NDA 38 sections
Savella HUMAN PRESCRIPTION DRUG LABEL 1 0456-1510 TABLET, FILM COATED 100 mg ORAL NDA 38 sections
Savella HUMAN PRESCRIPTION DRUG LABEL 1 0456-1512 TABLET, FILM COATED 12.50 mg ORAL NDA 38 sections
Savella HUMAN PRESCRIPTION DRUG LABEL 1 0456-1512 TABLET, FILM COATED 12.50 mg ORAL NDA 38 sections
Savella HUMAN PRESCRIPTION DRUG LABEL 1 0456-1525 TABLET, FILM COATED 25 mg ORAL NDA 38 sections
Savella HUMAN PRESCRIPTION DRUG LABEL 1 0456-1525 TABLET, FILM COATED 25 mg ORAL NDA 38 sections
Savella HUMAN PRESCRIPTION DRUG LABEL 1 0456-1550 TABLET, FILM COATED 50 mg ORAL NDA 38 sections
Savella HUMAN PRESCRIPTION DRUG LABEL 1 0456-1550 TABLET, FILM COATED 50 mg ORAL NDA 38 sections
SAVELLA HUMAN PRESCRIPTION DRUG LABEL 1 16590-845 TABLET, FILM COATED 25 mg ORAL NDA 35 sections
SAVELLA HUMAN PRESCRIPTION DRUG LABEL 1 16590-846 TABLET, FILM COATED 50 mg ORAL NDA 35 sections
SAVELLA HUMAN PRESCRIPTION DRUG LABEL 1 16590-847 TABLET, FILM COATED 100 mg ORAL NDA 35 sections
Savella HUMAN PRESCRIPTION DRUG LABEL 1 21695-650 TABLET, FILM COATED 25 mg ORAL NDA 34 sections
Savella HUMAN PRESCRIPTION DRUG LABEL 1 21695-651 TABLET, FILM COATED 50 mg ORAL NDA 34 sections
Savella HUMAN PRESCRIPTION DRUG LABEL 1 35356-545 TABLET, FILM COATED 50 mg ORAL NDA 33 sections
Savella HUMAN PRESCRIPTION DRUG LABEL 1 50436-9993 TABLET, FILM COATED 25 mg ORAL NDA 33 sections
Savella HUMAN PRESCRIPTION DRUG LABEL 1 54868-6024 TABLET, FILM COATED 100 mg ORAL NDA 33 sections
Savella HUMAN PRESCRIPTION DRUG LABEL 1 54868-6043 TABLET, FILM COATED 50 mg ORAL NDA 33 sections
Savella HUMAN PRESCRIPTION DRUG LABEL 1 55154-4626 TABLET, FILM COATED 50 mg ORAL NDA 36 sections
Savella HUMAN PRESCRIPTION DRUG LABEL 1 55154-4626 TABLET, FILM COATED 50 mg ORAL NDA 36 sections
Milnacipran HCl HUMAN PRESCRIPTION DRUG LABEL 1 65162-091 TABLET 12.50 mg ORAL ANDA 21 sections
Milnacipran HCl HUMAN PRESCRIPTION DRUG LABEL 1 65162-091 TABLET 12.50 mg ORAL ANDA 21 sections
Milnacipran HCl HUMAN PRESCRIPTION DRUG LABEL 1 65162-091 TABLET 12.50 mg ORAL ANDA 21 sections
Milnacipran HCl HUMAN PRESCRIPTION DRUG LABEL 1 65162-092 TABLET 25 mg ORAL ANDA 21 sections
Milnacipran HCl HUMAN PRESCRIPTION DRUG LABEL 1 65162-092 TABLET 25 mg ORAL ANDA 21 sections
Milnacipran HCl HUMAN PRESCRIPTION DRUG LABEL 1 65162-092 TABLET 25 mg ORAL ANDA 21 sections
Milnacipran HCl HUMAN PRESCRIPTION DRUG LABEL 1 65162-093 TABLET 50 mg ORAL ANDA 21 sections
Milnacipran HCl HUMAN PRESCRIPTION DRUG LABEL 1 65162-093 TABLET 50 mg ORAL ANDA 21 sections
Milnacipran HCl HUMAN PRESCRIPTION DRUG LABEL 1 65162-093 TABLET 50 mg ORAL ANDA 21 sections
Milnacipran HCl HUMAN PRESCRIPTION DRUG LABEL 1 65162-094 TABLET 100 mg ORAL ANDA 21 sections
Milnacipran HCl HUMAN PRESCRIPTION DRUG LABEL 1 65162-094 TABLET 100 mg ORAL ANDA 21 sections